| Outcome Measures: |
Primary: Blood Glucose Level, Measuring levels of glycemia (fasting glucose) in blood of patients in the placebo group and the chromium supplement group., Assessed for 16 weeks with 5 measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks), 16 weeks reported.|Blood Glucose Levels, Measuring levels of glycemia (HbA1c) in blood patients in the placebo group and the chromium supplement group., Assessed for 16 weeks with five measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks). 16 weeks reported. | Secondary: Lipid Levels, Measuring levels of TG (triglycerides), LDL and HDL-cholesterol in blood of patients in the placebo group and the chromium supplement group., Assessed for 16 weeks with 5 measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks), 16 weeks reported.|Blood Levels of Cytokines/Inflammatory Biomarkers, Measuring levels of reactive oxygen species (ROS) in blood of patients in the placebo group and chromium supplement group., Assessed for 16 weeks with 5 measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks), 16 weeks reported.|Blood Levels of Cytokines/Inflammatory Biomarkers, Measuring levels of Interleukin-6 (IL-6) in blood of patients in the placebo group and chromium supplement group., Assessed for 16 weeks with 5 measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks), 16 weeks reported.|Blood Levels of Cytokines/Inflammatory Biomarkers, Measuring levels of C reactive protein (CRP) in blood of patients in the placebo group and chromium supplement group., Assessed for 16 weeks with 5 measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks), 16 weeks reported.|Blood Levels of Cytokines/Inflammatory Biomarkers, Measuring levels of Leptin in blood of patients in the placebo group and chromium supplement group., Assessed for 16 weeks with 5 measurements. (0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks), 16 weeks reported.
|
